First of all, more homogeneous clinical studies with larger samples should be conducted to further determine the clinical significance of MNX1-AS1 in each cancer type; In addition, the roles of MNX1-AS1 in cancers and the corresponding mechanisms should be fully elucidated using in vitro cell model and in vivo animal models, such as MNX1-AS1-knockout mice and tumor organoid model; Furthermore, the anticancer effects of MNX1-AS1-targeting drugs should be evaluated in the patient-derived tumor xenograft (PDX) model and tumor organoid model. Here, PTGDR is linked to cancer.